Downstream Paclitaxel Released Following Drug-Coated Balloon Inflation and Distal Limb Wound Healing in Swine.
BTK, below the knee
CLI, critical limb ischemia
PCB, paclitaxel coated balloon
PTA, percutaneous transluminal angioplasty
SFA, superficial femoral artery
histopathology
paclitaxel-coated balloon
swine
translational
wound healing
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
06
10
2020
revised:
19
01
2021
accepted:
19
01
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
The authors evaluated the presence of paclitaxel and healing of distal hind limb wounds created in 27 swine using biopsy punches followed by paclitaxel-coated balloon (PCB) use in the iliofemoral arteries of healthy swine. After 14 and 28 days, no differences were seen in time course, appearance, and histopathology of wound healing between the single or triple PCB and uncoated balloon treatment despite clinically relevant paclitaxel concentrations in the skin adjacent to the healing wounds. Presence of paclitaxel downstream from the PCB treatment site does not impair the wound healing response of preexisting distal cutaneous lesions in healthy swine.
Identifiants
pubmed: 34095632
doi: 10.1016/j.jacbts.2021.01.012
pii: S2452-302X(21)00064-4
pmc: PMC8165120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
416-427Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Ms. Crookall, and Drs. Schulz-Jander, Tunev, and Melder are full-time employees of Medtronic PLC, the manufacturer of the IN.PACT Admiral product evaluated in the study. Dr. Granada is the CEO, and Dr. Kaluza is an employee of the Cardiovascular Research Foundation which receives research and educational grant support from Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Drug Des Devel Ther. 2014 Feb 20;8:279-84
pubmed: 24591817
Front Biosci. 2004 Jan 01;9:283-9
pubmed: 14766366
Cell Death Dis. 2020 Jan 22;11(1):45
pubmed: 31969555
Catheter Cardiovasc Interv. 2014 Jan 1;83(1):132-40
pubmed: 23703778
Circulation. 1997 Jul 15;96(2):636-45
pubmed: 9244237
J Vasc Interv Radiol. 2019 Jan;30(1):103-109
pubmed: 30527654
JACC Cardiovasc Interv. 2015 Jul;8(8):1115-1123
pubmed: 26117470
JACC Cardiovasc Interv. 2018 Dec 10;11(23):2357-2364
pubmed: 30522663
Life Sci. 2018 Oct 15;211:245-251
pubmed: 30243650
Ann Emerg Med. 1998 Dec;32(6):645-9
pubmed: 9832658
Eur J Pharm Biopharm. 2015 Oct;96:322-8
pubmed: 26318979
Thromb Haemost. 2009 Jan;101(1):201-6
pubmed: 19132209
Circ Cardiovasc Interv. 2019 Jun;12(6):e007702
pubmed: 31195825
N Engl J Med. 2015 Jul 9;373(2):145-53
pubmed: 26106946
J Vasc Interv Radiol. 2020 Feb;31(2):202-212
pubmed: 31954604
Eur J Vasc Endovasc Surg. 2019 Apr;57(4):578-586
pubmed: 30871939
Acad Emerg Med. 1998 Jun;5(6):583-6
pubmed: 9660284
PLoS One. 2013 Dec 31;8(12):e83992
pubmed: 24391863
JACC Cardiovasc Interv. 2020 Feb 24;13(4):431-443
pubmed: 32081236